Ratings by Cantor Fitzgerald (Pete Stavropoulos)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/16/2026 | AtaiBeckley Inc | ATAI | Downgrade | Neutral (Overweight) |
5.36 (7.22) |
34.7% | Details | |
| 7/13/2026 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/8/2026 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/29/2026 | ProMIS Neurosciences | PMN | New Coverage | Overweight (N/A) |
10.53 (15.19) |
44.25% | Details | |
| 6/22/2026 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/3/2026 | Rezolute | RZLT | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/15/2026 | Alector Inc. | ALEC | Upgrade | Overweight (Neutral) |
2.41 (1.50) |
-37.76% | Details | |
| 3/26/2026 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/25/2026 | Rezolute | RZLT | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/19/2026 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/17/2026 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/2/2026 | Definium Therapeutics Inc | DFTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | Axsome Therapeutics | AXSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/14/2026 | MindMed | MNMD | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | atai Life Sciences N.V | ATAI | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2026 | Novavax | NVAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/12/2026 | Stoke Therapeutics | STOK | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/5/2026 | Stoke Therapeutics | STOK | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | Rezolute | RZLT | Downgrade | Neutral (Overweight) |
10.94 (4.61) |
-57.86% | Details | |
| 12/1/2025 | Bright Minds Biosciences Inc. | DRUG | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/26/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/24/2025 | Novavax | NVAX | New Coverage | Overweight (N/A) |
8.36 (8.21) |
-1.79% | Details | |
| 10/22/2025 | Alector Inc. | ALEC | Downgrade | Neutral (Overweight) |
3.31 (2.41) |
-27.19% | Details | |
| 10/15/2025 | Cybin Inc. | CYBN | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/13/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/22/2025 | Dianthus Therapeutics | DNTH | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/24/2025 | Rezolute | RZLT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2025 | Jasper Therapeutics | JSPR | Downgrade | Neutral (Overweight) |
6.77 (0.89) |
-86.85% | Details | |
| 7/1/2025 | Arcturus Therapeutics | ARCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/26/2025 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/29/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/23/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Arcturus Therapeutics | ARCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | Pliant Therapeutics | PLRX | New Coverage | Neutral (N/A) |
3.44 (1.15) |
-66.57% | Details | |
| 3/3/2025 | Jasper Therapeutics | JSPR | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/18/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/10/2025 | Voyager Therapeutics | VYGR | New Coverage | Overweight (N/A) |
5.73 (3.17) |
-44.68% | Details | |
| 6/27/2024 | Dianthus Therapeutics | DNTH | New Coverage | Overweight (N/A) |
23.69 (105.60) |
345.76% | Details | |
| 1/8/2024 | Vera Therapeutics | VERA | New Coverage | Overweight (N/A) |
15.53 (38.50) |
147.91% | Details | |
| 8/8/2023 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2023 | Rezolute | RZLT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2023 | Acumen Pharmaceuticals, Inc. | ABOS | New Coverage | Overweight (N/A) |
5.45 (2.25) |
-58.72% | Details | |
| 5/1/2023 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2023 | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2023 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2023 | Eledon Pharamceuticals | ELDN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2023 | Jasper Therapeutics | JSPR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Arcturus Therapeutics | ARCT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/19/2022 | Arcturus Therapeutics | ARCT | New Coverage | Overweight (N/A) |
15.86 (6.05) |
-61.85% | Details | |
| 7/11/2022 | Pliant Therapeutics | PLRX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2022 | Rezolute | RZLT | New Coverage | Overweight (N/A) |
3.03 (10.94) |
261.06% | Details | |
| 5/25/2022 | Pliant Therapeutics | PLRX | New Coverage | Overweight (N/A) |
4.93 (3.44) |
-30.22% | Details | |
| 5/13/2022 | Eledon Pharamceuticals | ELDN | New Coverage | Overweight (N/A) |
2.41 (4.07) |
68.88% | Details | |
| 2/28/2022 | Jasper Therapeutics | JSPR | New Coverage | Overweight (N/A) |
3.74 (0.89) |
-76.2% | Details | |
| 12/29/2021 | Orchard Therapeutics | ORTX | New Coverage | Overweight (N/A) |
1.19 (16.70) |
1303.36% | Details | |
| 9/23/2021 | Annexon Biosciences | ANNX | New Coverage | Overweight (N/A) |
21.12 (5.80) |
-72.54% | Details |
